Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat

INTRODUCTION: Of the more than one million global cases of breast cancer diagnosed each year, approximately fifteen percent are characterized as triple-negative, lacking the estrogen, progesterone, and Her2/neu receptors. Lack of effective therapies, younger age at onset, and early metastatic spread...

Descripción completa

Detalles Bibliográficos
Autores principales: Tate, Chandra R, Rhodes, Lyndsay V, Segar, H Chris, Driver, Jennifer L, Pounder, F Nell, Burow, Matthew E, Collins-Burow, Bridgette M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3446342/
https://www.ncbi.nlm.nih.gov/pubmed/22613095
http://dx.doi.org/10.1186/bcr3192

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3446342/
https://www.ncbi.nlm.nih.gov/pubmed/22613095
http://dx.doi.org/10.1186/bcr3192

Ejemplares similares